MOH to appeal High Court ruling on nicotine vape exemption, says Dr Zaliha

Government Vows Court Battle Over Nicotine Vape Exemption: Health Ministry to Appeal Landmark Ruling

A significant legal challenge to the government's handling of nicotine-containing vape products is set to escalate, as the Ministry of Health announces its intention to appeal a recent High Court decision. The ruling, which questioned a previous administrative exemption, has ignited a debate about regulatory powers and public health strategies.

The controversy stems from a 2023 decision to temporarily exempt nicotine liquids and gels from certain provisions of the Poisons Act 1952. This move, according to former Health Minister Dr. Zaliha Mustafa, was a strategic maneuver to bring a burgeoning, largely unregulated industry under official oversight.

A Regulatory Tightrope Walk

Dr. Zaliha defended the 2023 exemption, framing it as a pragmatic response to a reality where nicotine vape products were already widely available, particularly to younger demographics. She highlighted the increasing ineffectiveness of existing enforcement mechanisms against a growing black market.

The High Court's recent decision favored a judicial review application brought by several health advocacy organizations. These groups challenged the legality and rationale behind the exemption, arguing it undermined public health efforts. The court's judgment has now prompted the Ministry of Health to seek recourse at the Court of Appeal.

The Ministry views the ongoing legal process as crucial for clarifying the boundaries of executive authority in policy-making, especially when national strategic interests are at stake. Dr. Zaliha emphasized that with the appeal pending, definitive conclusions are premature.

Context is Key: The Rise of the Vape Industry

The government's 2023 decision, Dr. Zaliha explained, must be understood within the context of a rapidly expanding vape industry. At the time, nicotine vape products were openly traded, often circumventing existing legal restrictions.

Enforcement under the Poisons Act 1952 had proven increasingly difficult to manage the widespread distribution of these products. Many were entering the market through illicit channels, lacking any form of regulation or safety monitoring.

The exemption, she argued, was a decisive step designed to bring the multi-billion-ringgit vape sector into a structured, regulated framework. This would allow authorities to monitor, tax, and control these products more effectively, rather than allowing unchecked underground trade to persist.

A New Legislative Framework

This strategic shift was preceded by extensive discussions at the Cabinet level. Subsequently, the Control of Smoking Products for Public Health Bill was introduced in Parliament in June 2023, aiming to close the identified legal loophole.

This legislation has since been enacted as the Control of Smoking Products for Public Health Act 2024 (Act 852). The new law provides a comprehensive regulatory structure for tobacco products, vape devices, and nicotine liquids, critically prohibiting sales to minors.

With Act 852 now fully operational, the regulatory gap has been addressed. Malaysia now possesses a more robust ecosystem for safeguarding public health, particularly for the younger generation.

Shared Goals, Different Paths

While acknowledging the concerns raised by health advocacy groups, Dr. Zaliha expressed respect for the court's decision as an integral part of the nation's democratic processes. She underscored that this system of checks and balances signifies a healthy democratic society.

Ultimately, the government and non-governmental organizations share a common objective: the protection of public health. The differing approaches highlight the complexities of balancing public health imperatives with regulatory frameworks and industry dynamics.

Government legal representatives had contended during the judicial review proceedings that the case had largely become academic. This was due to the subsequent enactment of Act 852, which effectively superseded the regulatory vacuum that the exemption had temporarily addressed. The appeal signifies the government's commitment to defending its policy decisions and ensuring a clear legal precedent for future regulatory actions concerning emerging health products.